Finally, the tumor-specific expression of CDH17 has inspired multiple therapeutic strategies, including cellular immunotherapies, antibody–drug conjugates, immunotoxins, radiolabeled agents, and engineered delivery platforms, all designed to selectively target CDH17-expressing cells while minimizing off-target toxicity. The gene discussed is CDH17; the disease is neoplasm.